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Abstract
Background: The Whitehall II (WHII) study of British civil servants provides a unique source of longitudinal data to
investigate key factors hypothesized to affect brain health and cognitive ageing. This paper introduces the multi-modal
magnetic resonance imaging (MRI) protocol and cognitive assessment designed to investigate brain health in a random
sample of 800 members of the WHII study.
Methods/design: A total of 6035 civil servants participated in the WHII Phase 11 clinical examination in 2012–2013. A
random sample of these participants was included in a sub-study comprising an MRI brain scan, a detailed clinical and
cognitive assessment, and collection of blood and buccal mucosal samples for the characterisation of immune
function and associated measures. Data collection for this sub-study started in 2012 and will be completed by
2016. The participants, for whom social and health records have been collected since 1985, were between 60–85
years of age at the time the MRI study started. Here, we describe the pre-specified clinical and cognitive
assessment protocols, the state-of-the-art MRI sequences and latest pipelines for analyses of this sub-study.
Discussion: The integration of cutting-edge MRI techniques, clinical and cognitive tests in combination with
retrospective data on social, behavioural and biological variables during the preceding 25 years from a well-established
longitudinal epidemiological study (WHII cohort) will provide a unique opportunity to examine brain structure and
function in relation to age-related diseases and the modifiable and non-modifiable factors affecting resilience against
and vulnerability to adverse brain changes.
Keywords: Epidemiology, Magnetic resonance imaging, Diffusion tensor imaging, White matter, Functional MRI,
Connectome, Resting state brain networks, Neuropsychology, Dementia, Affective disorders
Background
Over the next few decades, increases in life expectancy
will result in fundamental changes to the population struc-
ture. Associated with this demographic change, health and
social care services will need to cope with a greater preva-
lence of mental and neurological disorders. Clinical de-
pression and cognitive decline have a combined estimated
prevalence of 7-20% in the population over 65 years [1-4].
Furthermore, according to some estimates, the number of
people with neurodegenerative disorders will quadruple in
the next 20 years causing a significant increase in the cost
of care [5]. To extend the productive period in citizens’
lives and to reduce costs of care in late life a greater know-
ledge of prevention and treatment of these common con-
ditions is needed. This will not be possible without a
better understanding of the causal mechanisms of disease
and, equally importantly, the factors associated with resili-
ence to age-related dysfunction [6].
The Whitehall II (WHII) study of 10,308 British civil
servants provides a remarkable source of longitudinal data
to explore factors hypothesized to affect brain health and
cognitive ageing (Table 1). The cohort was established in
1985 at University College London (UCL) with the aim of
advancing knowledge of the causal chain through which
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social circumstances influence health [7]. By September
2011, the study had acquired 25 years of rich social, behav-
ioural and biological data enabling its transformation into
a unique study of ageing. Of the original 10,308 non-
industrial civil servants recruited in Phase 1, 6035 par-
ticipated in the ‘Phase 11’ assessment in 2012–13. As
participants in this study continue into older adult life,
the research now focuses on life course factors affecting
health and personal functioning at older ages.
We randomly selected 800 WHII Phase 11 participants
to take part in the WHII imaging sub-study, which in-
cludes a detailed clinical and cognitive assessment, meas-
urement of immune parameters and a magnetic resonance
imaging (MRI) scan. MRI scans provide a non-invasive
window into the living brain, giving unique access to un-
derstanding normal and pathological processes that affect
brain structure and function. Incorporating state-of-the-
art imaging techniques and cognitive measures with the
WHII’s longitudinal dataset of social, behavioural and bio-
logical variables, represents a unique opportunity to study
the ageing process and to directly link 25-year exposure
history to old-age cognition and a variety of measures of
‘brain health’. Analysis of immunological variables and
linkage of these studies with behavioural and imaging data
enables a more comprehensive investigation of the patho-
physiological processes of dysfunction and cognitive im-
pairment in later life.
In this paper, we provide a description of the study’s or-
ganisation and funding structure, its participants’ inclusion/
exclusion criteria and of the cognitive, imaging and blood
specimen protocols employed in the study. For the imaging
protocol, careful consideration has been given to harnessing
the most recent technical developments, whilst maintaining
clinical relevance. A preliminary description of the tech-
niques to be used to pre-process and examine MRI-related
measures will also be presented, and results of a direct
comparison between a recently developed and a more
standard MRI acquisition approach for investigating brain
functional organization will also be shown. We provide an
overview of our original hypotheses at the time of applica-
tion for funding.
Methods/design
Study organization and funding
The sub-study is funded by the Lifelong Health and Well-
being Phase-3 programme grant “Predicting MRI abnor-
malities with longitudinal data of the Whitehall II sub-
study” (MRC-G1001354; Ebmeier KP (PI), Geddes JR,
Kivimäki M, Mackay CE, Singh-Manoux A, Smith SM), as
well as the HDH Wills 1965 (English Charity Register:
1117747; Ebmeier KP (PI)), and the Gordon Edward Small
Charitable (Scottish Charity Register: SC008962; Ebmeier
KP (PI)) Trusts. Collection of blood and buccal mucosal
samples for a characterisation of immune function and as-
sociated measures is funded by the UK Medical Research
Council programme grant K013351 (“Adult determinants
of late life depression, cognitive decline and physical func-
tioning - The Whitehall II Ageing Study”, Kivimäki M
(PI), Singh-Manoux A, Brunner E, Batty GD, Kumari M,
Ebmeier KP, Hingorani A) and the ESRC professional fel-
lowship scheme to Kivimäki.
Ethical approval was granted generically for the “Protocol
for non-invasive magnetic resonance investigations in
healthy volunteers” (MSD/IDREC/2010/P17.2) by the Uni-
versity of Oxford Central University / Medical Science Div-
ision Interdisciplinary Research Ethics Committee (CUREC/
MSD-IDREC), who also approved the specific protocol:
“Predicting MRI abnormalities with longitudinal data
of the Whitehall II sub-study” (MSD-IDREC-C1-2011-
71). The Health Research Authority NRES Committee
Table 1 Phases of Whitehall II with available measures
Phase 1
1985-88
Phase 3
91-93
Phase 5
97-99
Phase 7
03-04
Phase 9
07-09
Phase 11
12-13
Ages [years] 35-55 39-64 45-69 50-74 55-79 60-85
Participants [n] 10308 8637 7830 6967 6755 6035
Social circumstances & behaviour, smoking, alcohol, exercise, sleep diet × × × × × ×
Biological measures: blood pressure, BMI, lipids, glucose, insulin, stored blood (−80C) × × × × × ×
2-h oral glucose tolerance test – × × × × ×
Inflammatory markers – × × × × –
Autonomic (HRV) – – × × × ×
Genetic material – – – × × ×
Psychosocial factors: work, social support, − participation, care provision × × × × × ×
Health outcomes: CHD, stroke, diabetes, cancer, mortality, medications × × × × × ×
Function: physical, social & mental × × × × × ×
Cognitive tests, physical/lung function tests – – × × × ×
× = present; – = absent.
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South Central – Oxford B approved the Study: “The
Whitehall II Immune Function Sub-study” (REC refer-
ence: 13/SC/0072, IRAS project ID: 120516).
The study follows the Medical Research Council (MRC)
Policy on data sharing, i.e. images and other data will be
available for analysis by other groups after completion of
the study, as is the case with the Whitehall II study (see
http://www.ucl.ac.uk/whitehallII/data-sharing [8,9].
Participants’ recruitment and cognitive protocol description
Participants
In order to make the sample as representative as possible
of the cohort at baseline, a random sample of 800 WHII
Phase 11 participants willing and able to give informed
consent have been invited to attend the imaging sub-study
at the Oxford Centre for Functional MRI of the Brain
(FMRIB). To achieve a sufficient number of participants
with depression, we added 30 participants with depressive
symptoms based on previous WHII clinical examinations.
We excluded participants with contraindications to MRI
scanning (including but not limited to a history of claus-
trophobia, certain metallic implants and metallic injury to
the eye) or who were unable to travel to Oxford without
assistance. A schematic flow-chart describing the different
stages of the study is provided in Figure 1.
Clinical and cognitive assessment
Each participant recruited for the WHII imaging sub-
study undergoes a detailed clinical and cognitive assess-
ment lasting up to two hours.
The clinical assessment consists of a (A) self-
administered questionnaire, a (B) semi-structured clin-
ical interview and (C) cognitive assessment (median =
56 minutes, interquartile range: 51–61 minutes).
Self-administered questionnaire
General Health Questionnaire-30 (GHQ-30; [10]): The
GHQ-30 is a 30-item self-administered screening ques-
tionnaire for the detection of psychiatric illness that ac-
companies ill-health, in non-psychiatric clinical and
community settings (routinely applied from scan 200).
Mood Disorder Questionnaire (MDQ; [11]): The MDQ
is a brief self-report questionnaire for the assessment of life
time history of bipolar disorders, based on the DSM-IV.
Centre for Epidemiological Studies Depression Scale
(CES-D; [12]): The CES-D is short self-report scale that
measures major depressive symptomatology in the general
population.
State and Trait Anxiety Inventory (STAI; [13]): The
STAI measures both S (state)- and T (trait)-Anxiety in
clinical and research settings [14]. It is a self-administered
questionnaire that consists of twenty statements assessing
how the individual feels at the moment (S-Anxiety) and
twenty assessing how they generally feel (administered to
n = 15 before routinely applied from scan 200).
CHAMPS Physical Activity Questionnaire for Older
Adults [15]: The CHAMPS is a self-administered physical
activity questionnaire for older persons. Participants re-
port the weekly frequency and duration of various physical
activities, typically undertaken by older adults, allowing
calculation of metabolic equivalent of task (MET) and cal-
oric expenditure values per week.
Locus for Causality Exercise Questionnaire (LCE; [16]):
The LCE is a 3-item self-administered scale that assesses
how much an individual feels that they choose to exercise
(internal perceived locus of causality) rather than have to
exercise for some reason (external perceived locus of caus-
ality). It is thought that individuals are more likely to en-
gage in physical exercise when the perceived locus of
causality is internal [17].
Pittsburgh Sleep Quality Index (PSQI; [18]): The PSQI
is a self-rated questionnaire made up of seven component
scores that assess sleep quality and disturbance over a one
month period in clinical and research settings.
Jenkins Sleep Questionnaire (JSQ; [19]): The JSQ is a 4-
item self-rated questionnaire for the assessment of sleep
disturbances over a month period.
Life-Orientation Revised (LOT-R; [20]): The LOT-R
was devised to measure individual optimism for future
events in the general population.
Life Events [21,22]): A modified version of the List of
Threatening Experiences questionnaire (LTE-Q) is used,
in which participants are asked about seven types of
stressful life events. Participants are asked to remember if
any of the events happened to them in the past, and when
they happened.
MacArthur stress reactivity questionnaire [23]: It is a
nine-item self-rated questionnaire in which the participant is
required to rate nine statements on a 5-point scale, regarding
to how they handle their emotions in stressful situations.
Penn State Worry Questionnaire Ultra-brief Version
(PSWQ; [24]): The PSWQ ultra-brief is the 3-item version
of the widely used self-report questionnaire for patho-
logical worry, the 16-item long PSWQ. The 3-items capture
pathological worry as defined by the DSM-IV; perceived
uncontrollability, multiple domains and high frequency of
worry. The PSWQ was introduced into the assessment
after scan 200.
Handedness ([25]): It is a self-administered questionnaire
that assesses which is the participant’s preferred hand to
complete a list of twelve tasks, as well as left-handedness in
the family.
Participants also provide information on medical history
(detailing hospitalizations, longstanding illnesses, diseases
or medical conditions), alcohol and nicotine intake, and
general information, such as age and education. Their
blood pressure is measured twice in a sitting position, after
Filippini et al. BMC Psychiatry 2014, 14:159 Page 3 of 16
http://www.biomedcentral.com/1471-244X/14/159
the cognitive protocol (OMRON HEM-907; OMRON
Healthcare UK Ltd., Milton Keynes).
Semi-structured clinical interview
Structured Clinical Interview for DSM-IV-TR Axis I Dis-
orders [26]: The SCID-I is a semi-structured interview
for diagnosing current and past DSM-IV Axis I disorders
and is administered by a trained graduate psychologist
or psychiatrist.
Further structured assessments
Further tests were performed when the clinical history and
SCID data of the participant suggested a diagnosis and
indicated that a more detailed assessment was required (the
number of each test carried out so far is listed in brackets):
Hamilton Depression Scale (HAMD; [27]): The HAMD
is a 17-item severity scale administered to individuals di-
agnosed with ‘affective disorder of depressive type’. It
has been devised to quantify the intensity of the depres-
sive symptoms of the patient, based on the necessary in-
formation elicited by the interviewer. This scale was
administered to n = 16 participants currently symptom-
atic on the SCID-I [26].
Young Mania Rating Scale (YMRS; [28]): The YMRS is
an 11-item rating scale for the assessment of manic
symptoms based on the subjective report of the patient’s
Figure 1 Flow-chart summarising the stages of the WHII imaging sub-study.
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experience over the past forty-eight hours. It follows a
rating style of symptom severity similar to that of the
HAMD [27] and is administered to participants cur-
rently symptomatic on the SCID-I [26] (n = 2).
Yale-Brown Obsessive Compulsive Scale (Y-BOCS;
[29,30]): The Y-BOCS is a clinician-rated ten-item scale of
the severity of symptoms of obsessive-compulsive disorder,
with separate subtotals for obsessions and compulsions.
This scale is applied to participants currently symptomatic
on the SCID-I [26] (n = 0).
CAGE Questionnaire [31]: Four questions make up
this questionnaire to detect dependence on alcohol. They
request information on whether the individual needs to
“Cut down” their drinking, feels Annoyed by criticism of
their drinking, feels Guilty about their alcohol use, and
whether they use alcohol first thing in the morning as an
‘Eye-opener’. This scale is administered to participants
currently symptomatic on the SCID-I [26] (n = 6).
Brief Psychiatric Rating Scale (BPRS; [32]): The BPRS
is an 18-24-point rating scale for the assessment of
psychotic symptoms, and is used in both clinical and re-
search settings. This scale is administered to participants
currently symptomatic on the SCID-I [26] (n = 0).
Cognitive assessment
Cognitive test battery administered to all participants:
Montreal Cognitive Assessment (MoCA; [33]): The MoCA
is a 30-point cognitive screening test assessing multiple
cognitive domains: a) visuo-spatial abilities (4 points),
assessed using a three-dimensional cube-drawing (1 point)
and a clock-drawing task (3 points); b) short-term memory
recall task (5 points), which involves learning 5 nouns and
recalling them approximately 5 minutes afterwards; c) ex-
ecutive function (3 points), which include an alternation
task (1 point) and a verbal abstraction task (2 points); d) at-
tention, orientation and working memory (6 points), which
are evaluated using a forward- and backward-digit task (2
points), a sustained attention task (1 point), and a serial
subtraction task (3 points); e) language (6 points), which is
measured using a three-item naming task (3 points), the
repetition of two syntactically complex sentences (2 points)
and a phonemic fluency task (1 point); and f) orientation to
time and space (6 points). Participants receive an additional
(1 point) if their education level is ≤ 12 years. Since the
MoCA assesses multiple cognitive domains, it is a useful
cognitive screening tool for several neurological diseases,
such as Parkinson’s disease, vascular cognitive impairment,
Huntington’s disease, multiple sclerosis, and other condi-
tions, such as traumatic brain injury, depression and
schizophrenia [33,34].
Trail Making Test (TMT) versions A and B ([35,36]:
The TMT is a visual attention and task-switching test
consisting of two parts in which the subject is instructed
to connect a set of twenty-five consecutive dots (A:
numbers and B: numbers and letters) on a sheet of paper
as fast as possible while still maintaining accuracy. It
provides information about visual search speed, speed of
processing, mental flexibility, as well as executive func-
tioning [36]. It is sensitive to the detection of cognitive
impairment including Alzheimer’s disease [37].
Rey Complex Figure Test and Recognition Trial (RCFT;
[38,39]): The RCF involves copying and then recalling a
complex geometric diagram at increasing time intervals
[40]. Different cognitive abilities are needed for a correct
performance, including visuo-spatial abilities, memory,
attention, planning, and working memory. It is used to
investigate the effects of brain injury and to test the
presence of neurodegenerative conditions [41].
Verbal fluency test (adapted from the Addenbrooke’s
Cognitive Examination Revised (ACE-III) [42]): The verbal
fluency test requires participants to say as many words as
possible from a category (animals) in a specified time
(60 seconds). It is used to investigate the presence of cog-
nitive impairment, neurodegenerative and psychiatric dis-
orders [43].
Hopkins Verbal Learning Test-Revised (HVLT-R; [44]):
The HVLT-R test provides a measure of verbal learning
and memory ability [45,46]. The participant is required
to learn a list of twelve words over the course of three
trials, and recall and recognise them at increasing time
intervals. It is widely used to test the presence of amnes-
tic disorders [47,48].
Boston Naming Test (BNT-60; [49]): The BNT-60 is a
60-item test graded in difficulty used to measure semantic
memory ability and requires naming of a series of images
shown to the participant [50]. It is used in individuals with
aphasia or any language disturbance caused by neurological
insults, such as stroke or neurodegenerative disorders [51].
Digit Span (DS) and Coding (DC) tests from the
Wechsler Adult Intelligence Scale - Fourth Edition (WAIS-
IV; [52]): The DS test is used to investigate short-term
memory abilities. It includes recall of a lengthening list
of digits forwards, backwards, and rearranged in ascend-
ing sequence (DSF, DSB, DSS) [53,54]. In the DC test
participants have to write the appropriate novel symbol
for each number within a given time.
Test of Premorbid Functioning (TOPF; [55]): The TOPF
consists of a list of seventy written words, which must
be read aloud and is marked according to pronunciation.
The TOPF is used to estimate an individual's level of in-
tellectual functioning before the onset of injury or ill-
ness. Premorbid IQ can be calculated from the raw
score, adjusted for sex and years of education.
Dots and letters (adapted from the Addenbrooke’s Cog-
nitive Examination III; [42]): The participant is asked to
count four sets of dots without pointing to them and
identify four partially drawn letters. These tasks assess
perceptual abilities.
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CLOX [56]: The CLOX is a clock drawing task; in the
first part the participant is given a set of instructions to
draw a clock and in the second part the examiner draws a
clock face, which the participant then has to copy. The
CLOX was designed to assess executive impairment and
non-executive failure, and is used to discriminate demen-
tia sub-groups [56].
Cambridge Neuropsychological Test Automated Battery
Reaction Time touchscreen version (CANTAB RTI; CAN-
TABeclipse 5.0; Cambridge Cognition Ltd. www.camcog.
com): The CANTAB RTI is a computerised (touchscreen)
latency task that measures latency and movement time
without having to control for tremor. The task is divided
into a simple and 5-choice reaction time stage. During the
task the participant must react as soon as a yellow dot ap-
pears; moving their finger on the screen from a pre-
defined location to the location of the yellow dot. In the
simple stage the yellow dot always appears in the same lo-
cation, and in the five-choice stage in one out of five po-
tential locations. The CANTAB RTI is often used to assess
visuo-spatial and visuo-motor coordination abilities [57],
motor speed [58], and understand sustained attention and
reaction time [59].
Purdue Pegboard Test [60,61]: The Purdue Pegboard
measures two types of dexterity; gross movement of the
fingers, hands and arms, and fine fingertip dexterity. The
participant places pins into a row of holes using right, left
and both hands (gross movement) and assembles a set of
structures from pins, collars and washers using both hands
(fine dexterity) as fast as they can, within a given time.
The Purdue Pegboard test was devised for employee selec-
tion for industrial jobs but is also used in clinical settings.
Impaired peg placement was found among patients with
Parkinson’s disease [62,63]), Huntington’s disease [62] and
schizophrenia [64]. The Purdue Pegboard can also aid
lateralization of function [65]. Healthy older people with-
out neuropsychiatric or other disease who showed MRI
white matter hyperintensities (WMH) performed worse
on the assembly subtest (fine dexterity) than those without
WMH [66].
Imaging protocol description
Scanning is carried out at the Oxford Centre for Func-
tional MRI of the Brain (FMRIB) using a 3 T Siemens
Magnetom Verio (Erlangen, Germany) Scanner with a 32-
channel receive head coil. The neuroimaging protocol
comprises both structural and functional sequences and
lasts approximately 50 minutes. MRI sequences include: a)
high-resolution T1-weighted, b) diffusion MRI (dMRI), c)
resting-state functional MRI (rfMRI), d) Fluid Attenuated
Inversion Recovery (FLAIR) and e) T2*. A full description
of the MRI parameters adopted in our sequences is pro-
vided in Table 2.
T1-weighted
This sequence is primarily used to study grey matter (GM)
structural macroscopic tissue in both cortical and subcor-
tical brain regions. GM reductions have been widely asso-
ciated with impending disease and age-related cognitive
dysfunction [67-69].
A Multi-Echo MPRAGE (MEMPR) with motion correc-
tion, developed at the Massachusetts General Hospital
(MGH, Boston), was employed [70,71]. This sequence has
the advantage of combining the properties of the classical
MPRAGE sequence, which has high contrast aiding cor-
tical segmentation, with Multi-Echo FLASH, which im-
proves segmentation of subcortical regions.
The pre-processing pipeline includes: a) re-orientating
images to the standard (MNI) template, b) bias field cor-
rection, c) registration to the MNI template using both
linear (FLIRT) and non-linear (FNIRT) registration tools
and d) brain extraction. Brain tissues are segmented
using FMRIB's Automated Segmentation Tool (FAST)
that allows extracting measures of total GM, WM and
cerebrospinal fluid (CSF). FIRST (http://fsl.fmrib.ox.ac.
uk/fsl/fslwiki/FIRST) [72], an automated model-based
segmentation/registration tool, is applied to extract sub-
cortical grey matter structures. Brain tissues and sub-
cortical regions are visually inspected to ensure an
accurate segmentation (Figure 2A,B).
Diffusion MRI (dMRI)
Diffusion MRI exploits the principles of traditional MRI to
measure the random motion of water molecules and subse-
quently to 1) infer information about white matter (WM)
microstructural properties and 2) delineate the gross axonal
organisation of the brain [73]. WM is characterised by bun-
dles of myelinated axons surrounded by myelin sheaths that
are built up by layers of membranes. This restricts diffusion
of free water molecules; i.e. the myelin layers and the
axonal membrane cause a lower restriction along than
across the axon and thus a higher anisotropy.
A number of strategies were used to minimise distor-
tions caused by, for example, magnetic susceptibility,
eddy-currents, and subject-motion. We employed mono-
polar diffusion encoding gradients with parallel imaging
(GRAPPA) to minimise echo time, which increases the
signal to noise ratio (SNR), at the cost of a small increase
in eddy-current distortion. We used a recently developed
dMRI correction strategy that takes advantage of the com-
plementary information from pairs of diffusion images ac-
quired with reversed phase-encoding (PE) directions to
correct for susceptibility-induced distortions [74]. A single
non-diffusion weighted (b-value = 0 s/mm2) volume with
reversed PE was combined with the non-reversed dMRI
data to estimate an off-resonance field, which is then ap-
plied to correct susceptibility distortions [75].
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Table 2 MRI sequences and parameters used in the study; S and T define Sagittal and Transversal orientation, respectively
Structural Functional
Sequence MEMPR FLAIR T2* dMRI Multiband Standard
Condition —————————— —————————— ————————— —————————— Resting Resting
TR in ms 2530 9000 36 8900 1300 3000
TE in ms 1.79/3.65/5.51/7.37 73 30 91.2 40 30
Flip angle 7° 150° 15° —————————— 66° 90°
Voxel in mm3 1x1x1 0.9x0.9x3 0.7x0.7x1.5 2x2x2 2x2x2 3x3x3
FoV read 256 220 220 192 212 192
FoV phase 100% 100% 81.3% 100% 100% 100%
Base resolution 256 256 320 96 106 64
Phase resolution 100% 100% 100% 100% 100% 100%
TI in ms 1380 2500 ————————— —————————— ——————————— ——————————
Bandwidth 651 Hz/Px 283 Hz/Px 170 Hz/Px 1680 Hz/Px 1814 Hz/Px 2368 Hz/Px
Orientation S T T T T T
b-value ——————— ————————— ———————— 1500 s/mm2 ————————— ———————————
N. of volumes ——————— ————————— ——————— ———————— 460 200
N. of directions ———————— ————————— ———————— 60 + 5 b = 0 s —————————— ———————————
Acquisition time 6 m 12 s 4 m 14 s 4 m 17 s 9 m 56 s 10 m 10 s 10 m
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The Pre-processing pipeline uses a recently developed
approach that simultaneously considers and corrects for
susceptibility-induced distortions, eddy-currents and head
motion (based on methods developed and applied to the
Human Connectome Project (HCP) diffusion MRI data
[74]). Briefly, a generative model approach is used to esti-
mate all types of distortion and a single resampling step
with spline interpolation is used to correct for all of them
simultaneously. Fractional anisotropy (FA), mean diffusiv-
ity (MD), axial diffusivity (AD) and radial diffusivity (RD)
maps are generated using DTIFit, part of FMRIB’s Diffu-
sion Toolbox (http://fsl.fmrib.ox.ac.uk/fsl/fdt), that fits a
diffusion tensor model at each voxel [76,77] (Figure 3, b).
Subsequently, crossing fibre orientations can be estimated,
and probabilistic tractography can be performed to recon-
struct white matter bundles and assess structural connect-
ivity [78].
Resting-state functional MRI (rfMRI)
rfMRI is used to investigate resting state networks (RSNs),
which comprise brain regions sharing a common time-
course of spontaneous fluctuations, and are thought to
represent functionally-critical neuronal networks that
reflect properties of functional brain organisation [79].
RSNs have been consistently observed across subjects,
sessions and functional brain imaging modalities (fMRI,
PET, EEG), and their presence has also been reported in
studies when participants were asleep, and in anaesthe-
tized monkeys and rats [79-85]. Although potentially
harder to interpret than task-based fMRI, the rfMRI ap-
proach has the considerable advantage of providing an
assay of brain function without requiring subjects to
undertake a specific task, particularly in cases where a
subject may be less able to understand and/or respond
to complex instructions.
Figure 2 T1-weighted imaging – analysis pipeline and initial volumetric results. A. Schematic figure representing the pipeline set up to
analyse T1-weighted images. The (A) raw T1-weighted image is initially (B) pre-processed (bias field corrected, neck cropped and brain extracted).
Subsequently, (C) brain tissues are segmented into gray matter (GM, red), white matter (WM, blue) and cerebrospinal fluid (CSF, green). Finally,
(D) subcortical brain regions are segmented. R and L define the right and the left hemisphere, respectively. B. Histogram of hippocampal sizes in
the first 300 participants. Volume measures in 10-3 ml.
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We compared a recently developed Multiband MRI
sequence [86,87] with ‘standard’ EPI. Multiband provides a
considerable improvement in temporal (Multiband: 1.3 sec-
onds vs. Standard EPI: 3 seconds) and spatial (Multiband:
2 mm isotropic vs. Standard EPI: 3 mm isotropic)
resolution, which allows: a) better definition of the spatial
maps, b) wider frequency range exploration in time-series
analyses and c) more detailed network analyses. To ensure
that the new multiband sequence was robust in our older
population, we acquired both sequences (standard and
multiband) on a subset of participants (N = 76). Results of
this comparison will be presented in the next section. In all
cases subjects were instructed to lie in dimmed light with
their eyes open, blink normally, but not to fall asleep.
rfMRI data pre-processing (motion correction, brain ex-
traction, high-pass temporal filtering with a cut-off of 100 s,
and field-map correction is carried out using MELODIC
(Multivariate Exploratory Linear Optimized Decomposition
into Independent Components, part of FSL http://fsl.fmrib.
ox.ac.uk/fsl/fslwiki/melodic/) [88,89]. In order to reduce the
presence of spatially and/or temporally-related artefacts a
data-cleaning approach is applied. Single-subject independ-
ent component analysis (ICA) is followed by an automatic
component classification with FMRIB's ICA-based X-
noiseifier (FIX) to identify and regress out the “signal” of
the artefactual components reflecting non-neuronal fluctu-
ations [90,91]. The pre-processed and “cleaned” functional
data are registered to the individual's structural scan and
standard space images using FNIRT, then optimized using
boundary-based-registration approach [92], and finally
spatially smoothed using an isotropic Gaussian kernel of
6 mm full width at half maximum (FWHM).
This project represents the first major application of the
Multiband sequence in older adults: therefore, as part of
the protocol development, the following were tested: a)
whether it was possible to identify the previously reported
set of “canonical” RSNs with the Multiband sequence
[81,88]; b) whether the Multiband sequence was effectively
associated with a “better” signal relative to a Standard EPI
sequence. For the first analysis MELODIC was used across
the first 50 consecutive participants and was able to detect
a set of RSNs that matched the “canonical” RSNs (Figure 4).
For the second analysis a direct comparison was made be-
tween Multiband and Standard EPI sequences that had
both been acquired on a subset (N =76) of participants. In
order to be able to compare the two sequences with respect
to spatial detail, spatial smoothing was not applied in this
analysis. Additionally, an independent set of RSNs’ spatial
maps, derived from data acquired for the Human Connec-
tome Project (HCP), was used as a common template to
extract time series and spatial maps from Multiband and
Standard EPI sequence data using the dual regression ap-
proach [93,94]. HCP templates are of higher resolution and
therefore contain more information compared with the
standard template maps. Group maps were then obtained
performing a one-sample t-test on the subjects’ spatial maps
(output of the second stage of dual regression) for each
component, calculating the corresponding z map and ap-
plying a mixture model correction to ensure comparable
A
B
Figure 3 Diffusion MRI - analysis pipeline and initial results for
fractional anisotropy. A. Schematic figure representing the raw data
(b=0) for both anterior-to-posterior and posterior-to-anterior encoding
directions (A) and after application of the two reversed phase encoding
(B). Red circles show before and after correction for distortions. Diffusion
MRI (dMRI)-derived metrics for fractional anisotropy (FA) and mean
diffusivity (MD) are also shown (C). R and L define the right and the left
hemisphere, respectively. B. Histogram of mean fractional anisotropy in
the first 300 participants.
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null distributions [95]. Figure 5 shows the quantile-
quantile plots (Q-Q plots) of the group maps against the
normal distribution. The group maps’ z-statistic distribu-
tion was expected to follow a normal distribution around
zero (random noise – the null part of the spatial maps),
while the tails should deviate from it according to the
RSNs’ identified signal. Therefore our results suggest that
Multiband sequence allows stronger RSN signal detection
(higher z-values) with respect to Standard EPI sequence.
Fluid attenuated inversion recovery (FLAIR)
This sequence is commonly used in clinical practice, for
example to characterise periventricular lesions adjacent to
the sulci, WM hyperintensities and WM lesions. Age-
related increase in the number of hyperintensities and/or
periventricular lesions has been widely reported [96,97].
Moreover, it has been shown that WM changes are associ-
ated with subtle structural and functional brain changes
[98], and with decline in essential cognitive abilities in
healthy elderly people [99]. Clinical ratings of FLAIR are
performed by trained neuroscientists based on visual rat-
ing scores. WM lesions and/or hyperintensities are visually
identified on FLAIR images by three independent raters
who make assessments blind to demographic details. All
axial slices of each subject are visually inspected. Peri-
ventricular and deep WM hyperintensities are rated separ-
ately using a 4-point ordinal scale from 0–3; the sum of
these two ratings lead to the total Fazekas score (an inte-
ger from 0–6) [100] (Figures 6A and B).
T2* (T2 star)
The T2* sequence allows the identification of cerebral
microbleeds, which reflect small deposits of the iron-
storing protein hemosiderin in the brain and may be a sign
of cerebral small-vessel disease [101,102]. Microbleeds can
be found all over the brain and have been shown to be
Figure 4 Resting state networks (RSNs) derived from Multiband data. Images represent group maps of 50 subjects. All RSN maps are
thresholded at Z = 3. R and L define respectively the right and the left hemisphere. Maps reported here are not smoothed.
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associated with neurological dysfunction and both clin-
ical and cognitive impairment [103,104]. Their under-
lying mechanism is still under investigation but the
deleterious effect, probably due to inflammatory effects,
has been proved to affect neuron functionality and/or
cortical cerebral activity [105]. All axial slices of T2*
images are visually explored performed by trained neu-
roscientists and microbleeds identified (Figure 6C).
Blood specimen protocol for the characterization of
immune function
Following the MRI examination, blood samples (3 × 8 ml)
and two buccal mucosal epithelial samples are taken from
each participant. Blood samples are drawn using Vacutai-
ner CPT tubes (Becton Dickinson) in a single venepunc-
ture, inverted 8 times to mix anticoagulant additive with
blood and processed within two hours of collection. Buc-
cal mucosal epithelial cells are collected by nylon swabs
(microbiome sample) and by twirling the brush against the
epithelium and shaking the brush in RNAlater solution for
15 sec to remove the cells (RNA sample). CPT tubes are
centrifuged in 1600 g for 30 min, allowing the separation
of serum from white blood cells and from red blood
cells. After the centrifugation, serum samples and per-
ipheral blood mononuclear cells (PBMCs), i.e. T cells, B
cells and NK cells are collected. PBMC cells are washed
with phosphate-buffered saline (PBS), counted under
microscope and cryopreserved using Cell Freezing
Medium (5% DMSO/11%HSA in PBS). All samples are
stored in −80°C for later analysis.
In order to investigate immune function in sample mater-
ial, PBMC cells are stimulated in vitro with αCD3/αCD28
mAb and with TLR2/1 ligand Pam3CSK4 (Pam3Cys) and
TLR4 ligand LPS in RPMI at 37°C in 5% CO2. Cells and su-
pernatants are collected after 6 and 24 h of stimulation and
stored for later analysis. RNA samples are investigated
using RT-PCR or transcriptomics, while serum samples
and cell supernatants are analysed with ELISA, Luminex or
Figure 5 Q-Q plots of group maps’ z values. Continuous lines
represent Q-Q plots for Multiband (green), Standard EPI (red) and
Human Connectome Project template (blue). Dashed-dotted lines
join the first and third quartiles of each distribution, to help evaluate
the linearity of the data.
Figure 6 FLAIR and T2* images. (A) periventricular hyperintensities (PWH) and (B) deep white matter (DWM) lesions on FLAIR. (C) T2* image
showing microbleed. R and L define the right and the left hemisphere, respectively.
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proteomics. Also, genomics/epigenomics and metabolomics
techniques as well as advanced bioinformatics tools will be
employed in the sample analysis.
Hypotheses
We will examine the following overarching hypotheses
in the sub-cohort recruited from WH II Phase 11:
(1) Early risk factors for cognitive dysfunction and late
onset depression (such as cardio-vascular risk, see (i.) to
(v.) below) will be associated with cerebral atrophy, re-
duced perfusion and impaired white matter integrity.
Resulting impaired cognitive function (as measured by
tests of episodic memory and executive function, see
below) will be associated with specific brain volumes mea-
sured by advanced methods such as voxel based analysis
and the automatic identification of specific structures,
such as hippocampus, and also with reduced white matter
integrity, quantified both globally [106], and homing in on
fibres of interest (including measures of structural con-
nectivity) [78];
(2) Resilience, measured in the sub-study directly [107]
and by the absence of depression and cognitive impair-
ment particularly in the presence of higher early risk (see
above), is associated with high white matter integrity
[108], and increased coherence of frontal regions in resting
state networks (which provides a measure of functional
connectivity) [109] or (compensatory) increased frontal
BOLD signal in a memory encoding task [93]. The most
important risk factors will be: (i) Antecedent vascular and
metabolic risk trajectories and morbidity (adverse major
blood lipids/apolipoproteins, hyperglycaemia and diabetes,
adiposity, high blood pressure, smoking, chronic inflam-
mation (C-reactive protein, interleukin 6), ECG abnormal-
ities, angina, myocardial infarction, stroke; Framingham
cardiovascular risk scores); (ii) low antecedent levels of
physical and mental activity (measured by questionnaire
[110-112]); (iii) baseline cognitive performance levels and
up to 15-year gradients of memory and executive function
decrement; (iv) history of depressed mood (3 to 8 repeat
measurements using the CESD [12] and the GHQ [10], (v)
genotype (APOE4 plus >48 k single nucleotide polymor-
phisms relevant to cardiovascular, metabolic and inflam-
matory syndromes [113]). The primary clinical hypotheses
which we will address are: a) The quality of frontal com-
pensatory activity will be affected by vascular risk,
hypertension, including absence of protective factors,
such as physical fitness, cardio-vascular and cerebrovas-
cular prophylaxis (aspirin, statins, antihypertensives), by
mental activity (“use it or lose it”), and by frontal lobe
atrophy (as observed in treatment resistant depression);
b) Time-trajectories derived from the WHII data set, e.g.
of cognitive function or depression scores, and vascular
risks-factor trajectories, will account for more of the diver-
sity of outcome than singular measurements during any
one of the previous follow-phases. This may allow imputa-
tions about the natural history of brain changes, but from
clinician’s point of view, the least labour and time-intensive
predictive test will be the most attractive. An important
clinical task would, therefore, be to determine the mini-
mum data set to predict outcome. c) Overall resilience, as
supported by the absence of current and past affective or
cognitive symptoms and good performance [78], can be
modelled longitudinally from observations antecedent to
medial temporal atrophy and frontal compensatory activity
and structural integrity (high FA in DTI scan) as described
in (a) and (b). In addition, we will address the following
specific hypotheses which are of independent interest but
will also support the primary findings: (d) Global cognitive
performance depends on both hippocampal and frontal in-
tegrity/connectivity and (compensatory) frontal activity
measured relatively higher frontal coherence within execu-
tive resting state networks; (e) Clinical impairment (out-
come) appears if functional frontal compensation does not
keep up with the degree of hippocampal and frontal atro-
phy observed; (f) First onset of depression after the age of
65 compared with no depression ever (outcome), matched
for age, sex, education, and potential causal factors, such as
vascular risk, is associated with reduced frontal/executive
network structural and functional connectivity; (g) Clinical
impairment may present as impaired cognition and/or as
major depressive syndrome depending on the frontal net-
works affected; (h) Greater hippocampal atrophy will be
observed with increasing age and APOE ε4 alleles; the ab-
sence of antidepressant medication; and among those with
a family history of dementia.
Discussion
The proposed programme of work will lead to the de-
velopment and validation of methods and measures to
integrate biological, physical, psychological, and socio-
economic markers or indicators of health and wellbeing
in later life, combining the Whitehall II repeat data
from 1985 onwards and the psychiatric assessment in
Phase 11 (2012–13), with detailed structural and func-
tional imaging data collected in 2012–2016.
Our focus will be on understanding the development
and impact of age-related conditions such as depression
and cognitive decline, their implications for employment
and work in later life, and specifically the neural mecha-
nisms of compensation for cognitive decline and resilience
to age-related stress by identifying the mechanisms of
neural scaffolding, and the factors and mechanisms associ-
ated with successful ageing in the face of brain changes
and risk factors. This hopefully will generate ways of pro-
tecting against age-related cognitive decline - an approach
that is urgently needed, given the current limited progress
in specifically preventing dementia.
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The programme requires the close collaboration between
the epidemiological and clinical team at UCL, the psychi-
atric and neuropsychological teams in the Oxford Depart-
ment of Psychiatry and the expertise and resources of the
neuroimaging centre at FMRIB. The research programme
not only crosses boundaries within the MRC, but also in-
volves engineering and physics components by virtue of its
complex MRI acquisition and analysis protocol. The
Whitehall II data-base includes extensive socio-economic
data, which will allow testing of relevant hypotheses that
cross over to risk factors employed in medical epidemi-
ology, and cover the entire adult life course from early
adulthood (age 35) to old age. The programme is relevant
to biological mechanisms within the neurosciences, as the
imaging methods employed will require further interpret-
ation and possible adjunct projects to investigate the bio-
logical mechanism responsible for MRI abnormalities.
There are of course other large-scale projects, including
the UK Biobank and the Connectome Project. One aspect
of specific added value in the Whitehall MRI substudy will
be the availability of a fine-grained chronological clinical
and life-style record with very detailed cognitive assess-
ment and comprehensive MRI data covering structural
and functional brain connectivity.
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